The people building onconephrology
Onconephrology and MGRS are young fields carried by a relatively small community of clinicians and scientists. This page recognizes the most prolific contributors — measured across 24,027 PubMed articles spanning eight subfields — and maps who works where. Every figure is counted in code from real records; it reflects publication volume, not a ranking of merit or influence.
The onconephrology field
Each circle is one recognized contributor, sized by paper count and clustered with the subfield they publish in most. Hover, tap, or focus a circle for their authorship mix and verifiable PubMed links.
- Onco-nephrology (general)
- Anticancer drug nephrotoxicity
- Checkpoint-inhibitor kidney injury
- MGRS & paraprotein kidney disease
- Myeloma cast nephropathy
- Anti-VEGF / TKI renal effects
- Tumor lysis & electrolytes
- Cellular therapy renal effects
Hover, tap, or focus a circle to see the contributor, their authorship mix, and verifiable PubMed links.
Most prolific overall
The 30 contributors with the most papers across the whole corpus. The tally links to each author’s PubMed bibliography.
10 first-author · 14 senior-author · 2002–2026
2 first-author · 10 senior-author · 2004–2026
15 first-author · 19 senior-author · 2003–2025
Leaders by subfield
The most-published contributors within each of the eight onconephrology subfields — so specialists in smaller areas are recognized alongside the high-volume generalists.
Onco-nephrology (general)
333 papersThe field named explicitly — reviews, consensus, and cross-cutting work.
Anticancer drug nephrotoxicity
8,641 papersChemotherapy, targeted agents, and immunotherapy injuring the kidney — this atlas's core.
Checkpoint-inhibitor kidney injury
618 papersImmune checkpoint inhibitor–associated acute interstitial nephritis and AKI.
MGRS & paraprotein kidney disease
4,858 papersMonoclonal gammopathy of renal significance and light-chain kidney injury.
Myeloma cast nephropathy
5,940 papersMultiple myeloma and plasma-cell dyscrasias with renal involvement.
Anti-VEGF / TKI renal effects
5,034 papersAnti-angiogenic proteinuria, hypertension, and thrombotic microangiopathy.
Tumor lysis & electrolytes
692 papersTumor lysis syndrome and cancer-therapy electrolyte disorders affecting the kidney.
Cellular therapy renal effects
627 papersCAR-T and cellular immunotherapy renal complications (CRS-associated AKI).
How this is measured
Eight renal-scoped PubMed queries define the corpus: onco-nephrology, anticancer drug nephrotoxicity, checkpoint-inhibitor kidney injury, MGRS & paraprotein disease, myeloma cast nephropathy, anti-VEGF/TKI renal effects, tumor-lysis & electrolytes, and cellular-therapy renal effects. Every matching article is retrieved in full (no sampling) and its author list parsed. Counts — total papers, first-author, senior-author, per-subfield — are tallied in code, never estimated, from 24,027 real records via the PubMed E-utilities API.
Known limits, stated plainly. Authors are grouped by surname plus given name; PubMed carries no universal author id in these records, so this deterministic key can occasionally split one person across name variants or merge two who share a name. Corresponding authorship is not reliably machine-extractable, so it is omitted rather than invented — first (lead) and last (senior/PI) authorship are the standard proxies. Senior-author credit is withheld on 50+ author consortium papers. This is a measure of publication volume within these queries, which favors long careers and high-output groups; it is recognition, not a verdict on scientific merit or influence.
Regenerated from PubMed on 2026-07-08. Educational content — not medical advice.